대한의료관련감염관리학회 Korean Society for Healthcare-associated infection Control and Prevention.

pISSN 0705-3797. eISSN 2586-1298.

Table. 1.

Table. 1.

Features of COVID-19 vaccination planned to be introduced in Korea

Platform Adenovirus vector [8,9,21,44,46] Neucleotide vaccine (mRNA) [6,7,45,47] Recombinant protein [14,15]
Vaccine name AZD1222 Ad26.COV2.S mRNA-1273 BNT162b2 NVX-CoV2373
Manufacturer AstraZeneca Janssen Moderna Pfizer-BioNTech Novavax
No. of doses/interval
Phase 3 2 doses/4 weeks 1 dose 2 doses/4 weeks 2 doses/3 weeks 2 doses/3 weeks
KDCA guidance 2 doses/8-12 weeks 1 dose 2 doses/4 weeks 2 doses/3 weeks
Vaccine efficacy ≥14 days after 2nd dose (all symptomatic): 70.4% (95% CI, 54.8-80.6%) ≥14 days after single dose (all symptomatic): 66.9% (95% CI, 59.1-73.4%) ≥14 days after 2nd dose (all symptomatic): 94.1% (95% CI, 89.3-96.8%) ≥7 days after 2nd dose: 95% (95% credible interval, 90.3-97.6%) ≥7 days after 2nd dose: 89.3% (95% CI, 75.2-95.4%)
Storage requirement 2℃-8℃ (6 months) 2℃-8℃ (3 months) or 9℃-25℃ (12 hours), −50℃ to −15℃ (6 months) 2℃-8℃ (1 month) 8℃-25℃ (12 hours) −80℃ to −60° (6 months) or −25℃ to −15℃ (14 days) or 2℃ to 8℃ (5 days)* after once thawed 2℃-8℃
Transporting temperature 2℃-8℃ 2℃-8℃ 2℃-8℃ −80℃ to −60℃ 2℃-8℃
Storage after first puncture 2℃-25℃ within 6 hours 2℃-8℃ within 6 hours or 9℃-25℃ within 2 hours 2℃-25℃ within 12 hours (After dilution) 2℃-25℃ within 6 hours

* An expiry date of Pfizer-BioNTech vaccine has been extended to 30 days when refrigerated between 2℃ to 8℃ (updated on 21st, May, 2021).

Abbreviation : CI, confidence interval.

Korean J healthc assoc Infect Control Prev 2021;26:3~15 https://doi.org/10.14192/kjicp.2021.26.1.3
© Korean J healthc assoc Infect Control Prev